| OA20.02 | HIV-resistant dual CD28/4-1BB costimulated CAR T cells mitigate HIV pathogenesis in humanized mice | Oral Abstract Session | Cellular immunity |
| OA20.05 | HIV-1 infection and the control of viral replication are associated with greater expression of interleukin-21 receptor on CD8+ T cells | Oral Abstract Session | Cellular immunity |
| PE03.01 | Breadth of CD8 T-cell mediated inhibition of HIV-1 replication correlates with breadth of epitope recognition mapped with a comprehensive Gag, Nef, Env and Pol potential T-cell Epitope (PTE) peptide set | E-poster | Cellular immunity |
| PE03.03 | Incidence, clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome (IRIS) among HIV patients on highly active anti-retroviral therapy (HAART) in the south west region of Cameroon | E-poster | Cellular immunity |
| PE03.04LB | Infection with a highly Gag pre-adapted virus broadens the proteins targeted by CTLs during acute HIV infection | E-poster | Cellular immunity |
| PU03.01 | Generation of HIV-specific CD4 and CD8 T-cell clones for use in HIV viral inhibition assays | Publication Only | Cellular immunity |
| HY01.01LB | VRC01 antibody prevention of HIV | Oral Abstract Session | Clinical trial results |
| HY01.02LB | Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084 | Oral Abstract Session | Clinical trial results |
| OA03.01 | Safety and single-dose pharmacokinetics of VRC07-523LS administered via different routes and doses | Oral Abstract Session | Clinical trial results |
| OA04.05LB | Trial design, enrollment status, demographics, and pharmacokinetics (PK) data from a blinded interim analysis from a phase 2a trial of Islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP) | Oral Abstract Session | Clinical trial results |